Inflammation and atherosclerosis: the value of the high-sensitivity C-reactive protein assay as a risk marker.

I. Jialal, S. Devaraj

Research output: Contribution to journalArticle

116 Citations (Scopus)

Abstract

C-reactive protein (CRP) is a prototypic marker of inflammation. Numerous prospective studies in healthy volunteers have confirmed that high-sensitivity CRP (hsCRP) predicts cardiovascular events (CVEs), and hsCRP seems additive to an elevated total cholesterol level and a total/high-density lipoprotein cholesterol ratio in men and women in predicting risk. In smokers and people with metabolic syndrome, hsCRP levels are elevated; in elderly people, there seems to be a relationship between hsCRP and CVEs and mortality. Several properties of CRP make it proatherogenic; however; pending further studies, it should be considered as a risk marker. In people with acute coronary syndromes, hsCRP measurement may be valuable. Elevated levels in the highest quantile seem to predict greater mortality and poorer prognosis in patients with unstable angina and myocardial infarction (MI). While hsCRP is a strong independent predictor of risk of future MI, stroke, peripheral arterial disease, and vascular death, the validity of hsCRP as a risk marker needs to be assessed in all populations. Weight loss, statin drugs, aspirin, and high-dose alpha tocopherol therapy could affect hsCRP. It has its greatest validity as an adjunctive measure in the primary prevention of cardiovascular disease.

Original languageEnglish (US)
JournalAmerican Journal of Clinical Pathology
Volume116 Suppl
StatePublished - Dec 2001
Externally publishedYes

Fingerprint

C-Reactive Protein
Atherosclerosis
Inflammation
Myocardial Infarction
Anti-Obesity Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Mortality
Peripheral Arterial Disease
Unstable Angina
alpha-Tocopherol
Primary Prevention
Acute Coronary Syndrome
Hypercholesterolemia
HDL Cholesterol
Aspirin
Blood Vessels
Healthy Volunteers
Cardiovascular Diseases
Stroke
Prospective Studies

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Inflammation and atherosclerosis : the value of the high-sensitivity C-reactive protein assay as a risk marker. / Jialal, I.; Devaraj, S.

In: American Journal of Clinical Pathology, Vol. 116 Suppl, 12.2001.

Research output: Contribution to journalArticle

@article{d62d85353d37431ebd563c02cf694511,
title = "Inflammation and atherosclerosis: the value of the high-sensitivity C-reactive protein assay as a risk marker.",
abstract = "C-reactive protein (CRP) is a prototypic marker of inflammation. Numerous prospective studies in healthy volunteers have confirmed that high-sensitivity CRP (hsCRP) predicts cardiovascular events (CVEs), and hsCRP seems additive to an elevated total cholesterol level and a total/high-density lipoprotein cholesterol ratio in men and women in predicting risk. In smokers and people with metabolic syndrome, hsCRP levels are elevated; in elderly people, there seems to be a relationship between hsCRP and CVEs and mortality. Several properties of CRP make it proatherogenic; however; pending further studies, it should be considered as a risk marker. In people with acute coronary syndromes, hsCRP measurement may be valuable. Elevated levels in the highest quantile seem to predict greater mortality and poorer prognosis in patients with unstable angina and myocardial infarction (MI). While hsCRP is a strong independent predictor of risk of future MI, stroke, peripheral arterial disease, and vascular death, the validity of hsCRP as a risk marker needs to be assessed in all populations. Weight loss, statin drugs, aspirin, and high-dose alpha tocopherol therapy could affect hsCRP. It has its greatest validity as an adjunctive measure in the primary prevention of cardiovascular disease.",
author = "I. Jialal and S. Devaraj",
year = "2001",
month = "12",
language = "English (US)",
volume = "116 Suppl",
journal = "American Journal of Clinical Pathology",
issn = "0002-9173",
publisher = "American Society of Clinical Pathologists",

}

TY - JOUR

T1 - Inflammation and atherosclerosis

T2 - the value of the high-sensitivity C-reactive protein assay as a risk marker.

AU - Jialal, I.

AU - Devaraj, S.

PY - 2001/12

Y1 - 2001/12

N2 - C-reactive protein (CRP) is a prototypic marker of inflammation. Numerous prospective studies in healthy volunteers have confirmed that high-sensitivity CRP (hsCRP) predicts cardiovascular events (CVEs), and hsCRP seems additive to an elevated total cholesterol level and a total/high-density lipoprotein cholesterol ratio in men and women in predicting risk. In smokers and people with metabolic syndrome, hsCRP levels are elevated; in elderly people, there seems to be a relationship between hsCRP and CVEs and mortality. Several properties of CRP make it proatherogenic; however; pending further studies, it should be considered as a risk marker. In people with acute coronary syndromes, hsCRP measurement may be valuable. Elevated levels in the highest quantile seem to predict greater mortality and poorer prognosis in patients with unstable angina and myocardial infarction (MI). While hsCRP is a strong independent predictor of risk of future MI, stroke, peripheral arterial disease, and vascular death, the validity of hsCRP as a risk marker needs to be assessed in all populations. Weight loss, statin drugs, aspirin, and high-dose alpha tocopherol therapy could affect hsCRP. It has its greatest validity as an adjunctive measure in the primary prevention of cardiovascular disease.

AB - C-reactive protein (CRP) is a prototypic marker of inflammation. Numerous prospective studies in healthy volunteers have confirmed that high-sensitivity CRP (hsCRP) predicts cardiovascular events (CVEs), and hsCRP seems additive to an elevated total cholesterol level and a total/high-density lipoprotein cholesterol ratio in men and women in predicting risk. In smokers and people with metabolic syndrome, hsCRP levels are elevated; in elderly people, there seems to be a relationship between hsCRP and CVEs and mortality. Several properties of CRP make it proatherogenic; however; pending further studies, it should be considered as a risk marker. In people with acute coronary syndromes, hsCRP measurement may be valuable. Elevated levels in the highest quantile seem to predict greater mortality and poorer prognosis in patients with unstable angina and myocardial infarction (MI). While hsCRP is a strong independent predictor of risk of future MI, stroke, peripheral arterial disease, and vascular death, the validity of hsCRP as a risk marker needs to be assessed in all populations. Weight loss, statin drugs, aspirin, and high-dose alpha tocopherol therapy could affect hsCRP. It has its greatest validity as an adjunctive measure in the primary prevention of cardiovascular disease.

UR - http://www.scopus.com/inward/record.url?scp=0035757218&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035757218&partnerID=8YFLogxK

M3 - Article

C2 - 11993695

AN - SCOPUS:0035757218

VL - 116 Suppl

JO - American Journal of Clinical Pathology

JF - American Journal of Clinical Pathology

SN - 0002-9173

ER -